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The concept of transdifferentiation, here de-
fined as the ability of a cell from one tissue type to
generate differentiated cells of another tissue type,
is highly controversial. Specifically, there is debate
surrounding the ability of circulating bone marrow
derived cells to generate lung-specific cell types.
Such transdifferentiated cells can either contribute
to the development of pathology, as in fibrosis, or
may be able to serve a protective function, as in
endothelial or epithelial regeneration. Publications
highly relevant to lung stem and progenitor cells,
postdating our prior review [1], are summarized in
table 1. We apologize in advance for any studies
omitted due to oversight or space limitations. Fur-
thermore, we did not exhaustively critique techni-
cal aspects of many of the studies individually. It is
important to remember that, where applicable,
each article variably characterized the starting cell
populations, that technical standards for determi-
nation of cell origin and phenotype by imaging
methods are in flux, and that few if any articles
have shown clonal expansion of transdifferentiated
lung cells. Our general approach in this brief up-
date, with some exceptions, is to state the take
home message of the study. We recommend that
critical analysis of each paper is necessary to de-
cide how well the data supports the conclusions.
Lung somatic stem cells. There are new data
regarding local cell renewal within distinct
anatomic and cellular lung compartments. Kim et
al. identified a regional bronchio-alveolar epithe-
lial stem cell population, confined to the junction
between airway and alveoli and expressing charac-
teristic markers, which was capable of clonal mul-
ti-potential growth, including generation of adeno-
carcinoma [2]. The extent of the proximal airway
and distal alveolar epithelium supported by this
stem cell niche remains to be determined. Starting
with mixed populations of dissociated tissue cells
from 3 adult human bronchi, Sabatini et al. cul-
tured fibroblasts that displayed markers common
to bone marrow stromal cells (MSCs), that re-
tained the ability to follow adipogenic, chondro-
genic, or osteogenic lineages and may contribute
to lung repair and remodeling [3]. Summer et al.
analyzed embryonic mouse lung side population
cells, capable of dye efflux analogous to bone mar-
row hematopoietic stem cells (HSCs), and charac-
terized them as a complex mixture of both
hematopoietic (CD 45+) and non-hematopoietic
(CD 45-) progenitors, the latter containing both
smooth muscle or endothelial progenitors that
when co-cultured formed tubular, vessel-like
structures [4]. The molecular characteristics and
full differentiation potential of the CD 45- lung
side population cells require further study.
Transdifferentiation. Bone marrow cells of
traditional hematopoietic lineages normally mi-
grate to the lungs, and this process is dramatically
accelerated in lung injury and pathology. Leuko-
cytes characteristic of acute and chronic inflam-
matory processes are undoubtedly physiologically
important, but the ability of circulating cells to
generate lung-specific cell types by fusion or
transdifferentiation is hotly debated, fueled by
both supportive and negative studies. In general,
the contribution of bone marrow to lung is direct-
ly correlated with the degree of lung injury, typi-
cally ablative radiation prior to bone marrow trans-
plant followed by experimental injury in animals,
or injury accompanying bone marrow or lung
transplantation in people. Abe et al. created para-
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Currently, there is great enthusiasm about potential
stem cell therapies for intractable diseases. We previously
reviewed the topic of stem cells in lung injury and repair,
including the role of endogenous, tissue (somatic) stem
cells and the contribution of circulating cells to the lung
parenchyma. Our purpose here is to provide a concise up-
date in this fast-moving field. New information and ongo-
ing debate focus attention on basic issues in lung stem cell
biology and highlight the need for additional studies to es-
tablish the feasibility of cell therapies to prevent or treat
lung diseases.
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SPC-GFP mice
Whole BM, HSC from 
SPC-GFP, and LacZ mice
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Lung Cell Type Formed 
/ Frequency
Putative bronchiole-alveolar epithelial
stem cell, co-expresses CCSP and SPC,
increased in oncogenic K-ras mouse
tumor model
MSC-like bronchial fibroblast 
that generates adipogenic, chondrogenic,
or osteogenic lineages
HSCs, endothelial cells, and smooth
muscle cells
Hematopoeitic cells, epithelial cells,
fibroblasts




Alveolar epithelium and endothelium,
~10% total GFP+
Reduced circulating endothelial cells 
in patients developing fibrosis
Endothelium of arterioles, reversal 
of hypertension
Increased progenitors associated with
improved survival
GFP+ fibroblasts present for 20 days
Cytokeratin 18 positive cells expressing
CFTR from MSCs
0.01% of airway epithelial cells positive
for CFTR
Bronchial ~1.4% and alveolar ~3.6%
chimerism, no cell fusion
Type II cells, ~0.55%
Type II cells, macrophages, endothelium,
qualitative
No donor lung cell types expressing GFP
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Table 1. - Recent studies addressing lung somatic stem cells and generation of lung cell types by exogenous 
progenitors or ES cells
BM = bone marrow, BMT = bone marrow transplant (with prior ablation), CCSP = Clara cell specific protein, CFTR = cystic fibrosis transmembrane regulator protein,
Di-acLDL = di-acetylated low density lipoprotein, eNOS = endothelial nitric oxide synthase, ES = embryonic stem cells, FISH = fluorescence in situ hybridization,
FACS = fluorescence activated cell sorting, GFP = enhanced green fluorescent protein, HLA = human leukocyte antigen, HSC = hematopoietic stem cells, LacZ =
gene for beta galactosidase, MSC = bone marrow stromal cells, adherent bone marrow cells, SCNT = somatic cell nuclear transfer (therapeutic cloning), SPC =
surfactant protein C, VEGF2 = vascular endothelial growth factor 2.
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biotic pairs of mice, one ubiquitously expressing
green fluorescent protein (GFP) and the other, wild
type [5]. After injuring the lungs of the wild type
mice, they observed GFP-positive hematopoietic
and lung parenchymal cell types. GFP-positive, fi-
broblast-like cells were cultured from the wild-type
lungs, but their clonal growth or ability to be pas-
saged was not assessed. Rojas and colleagues
found that myelo-suppression increased homing
and localization of a mixed, CD 45-depleted popu-
lation of donor MSCs to bleomycin-injured lung,
where they reportedly differentiated into fibrob-
lasts, type I and type II alveolar epithelium, and en-
dothelium [6]. After host irradiation and transplan-
tation of bone marrow side population cells highly
enriched for their stem cell potential, MacPerson
et al. detected Y chromosome-positive donor cells
expressing cytokeratin at a frequency of 0.8% in
recipient lung tissue [7]. Yamada et al. found that
LPS-induced lung inflammation recruited bone
marrow derived progenitor cells, which reported-
ly differentiated into endothelial and epithelial
cells and protected the lung [8]. In parallel, these
investigators identified circulating endothelial cell
progenitors in humans with bacterial pneumonia,
which were reduced in number when fibrosis en-
sued, further suggesting a role for bone marrow
derived cells in lung repair [9]. Work by the group
of Dr. Stewart showed that bone marrow-derived
endothelial-like progenitor cells reversed
monocrotaline-induced pulmonary arterial hyper-
tension in rats [10], and this preclinical data has
supported a human trial of endothelial progenitor
cell therapy for pulmonary hypertension
(http://www.stemcellnetwork.ca/news/articles.php
?id=889). A recent study suggests that increased
numbers of circulating endothelial-like progenitor
cells are associated with survival in human acute
lung injury [11]. Thus, while the actual prospects
remain unknown, pulmonary endothelial cell sup-
plementation with putative circulating progenitors
to treat or reverse vascular injury is at the forefront
of potential lung cell therapies. Also of note re-
garding cell therapy is that embryonic mouse lung
fibroblasts instilled down the trachea of elastase-
treated mouse lungs apparently penetrated into the
lung interstitium, where they persisted for 20 days
[12]. The prospects for treatment of lung diseases
characterized by epithelial dysfunction with bone
marrow-derived stem cells are less certain, and
hinge on the controversy surrounding the extent of
transdifferentiation, again here defined as the gen-
eration of cells of one tissue type by cells of a dif-
ferent tissue type. Wang and colleagues procured
MSCs from cystic fibrosis (CF) patients, intro-
duced a correct copy of the CFTR gene, and co-
cultured them with airway epithelial cells from CF
patients [13]. The studies suggested that CFTR
gene-corrected MSCs converted into airway ep-
ithelium and promoted chloride transport. Howev-
er, the magnitude of the correction in comparison
to normal chloride transport in non-CF epithelial
cells was not determined. In fact, a very recent
study in CFTR gene-deleted mice illustrated that
transdifferentiation followed by CFTR protein ex-
pression was extremely rare, occurring in 0.01% of
epithelial cells [14], arguing against the feasibility
of bone marrow transplantation to treat CF.
Sex-mismatched human bone marrow and
lung transplantation provides an opportunity to as-
sess transdifferentiation, and recent studies again
yielded conflicting results. Spencer et al. exam-
ined serial biopsies from 2 boys receiving female
lung allografts and suggested significant tissue
chimerism, namely, 1.6% and 3.6% of airway and
alveolar Y chromosome-positive epithelial cells,
respectively [15]. On the other hand, Zander et al.,
using a similar approach, typically found only one
Y chromosome-positive, cytokeratin-positive
alveolar epithelial cell, estimated to be 0.5% of
alveolar epithelium, in 9 of 25 specimens [16]. Al-
bera et al. studied 8 lungs from female donors
transplanted into male recipients, then explanted at
re-transplantation for chronic rejection, and also 3
lungs at autopsy from females receiving male bone
marrow transplants [17]. Their results were com-
pletely qualitative, but suggested the possibility of
exogenous cells contributing to lung epithelium.
Common to many investigations in this field, these
studies all rely on finicky and somewhat subjective
staining and imaging techniques, in this case made
even more difficult by variable tissue sampling,
post mortem changes, and/or the length of fixation.
Recent studies have revisited earlier animal
experiments that initially supported a bone marrow
contribution to lung parenchymal cells. Kotton et
al. used mice expressing GFP driven by the sur-
factant protein C (SPC) promoter, which is a spe-
cific reporter system for alveolar type II cells [18].
They transplanted bone marrow cells from these
mice into lethally irradiated adult mice, which
were then treated with bleomycin [19]. Similarly,
Chang et al. studied neonatal mice following bone
marrow transplantation from donors ubiquitously
expressing marker genes or from SPC-GFP mice
[20]. The investigators carefully employed flow
cytometry, deconvolution microscopy, and SPC
gene expression and reported the absence of alve-
olar epithelial reconstitution by whole bone mar-
row or HSCs. The results from both studies sug-
gest that artifactual co-localization of markers, in
the face of a flood of phagocytic hematopoietic
cell types, many dead cells, and abundant autoflu-
oresence in lung tissue, is more likely than actual
transdifferentiation. Another recent study in mice
reports absence of significant parenchymal en-
graftment of marrow-derived cells after endotoxin
or NO2 lung injury [21].
The literature to date highlights the technical
difficulty of definitively establishing transdifferen-
tiation of bone marrow-derived stem cells into lung
parenchymal cell types. We suggest that further
studies solely relying on imaging will not help to
resolve the controversy, and that additional ap-
proaches such as those illustrated in figure 1 will be
necessary. The ability to culture parenchymal cell
types of exogenous derivation from recipient lung,
as illustrated in figure 1A, would be supportive of
transdifferentiation. Since typical hematopoietic
lineage cell types can persist for many days in cul-
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ture, clonal growth and sub-passaging comparable
to endogenous lung cells would be stronger proof.
Furthermore, this method can theoretically be ap-
plied to human transplant tissues. The approach of
using donor cells with a reporter driven by a lung
specific promoter (figure 1B) has already been
tried, but with negative results [19, 20]. However,
false negatives are possible, and additional studies
using different constructs, donor populations, in-
juries, etc. are warranted. Unequivocal gain of
function in a deficient mouse (figure 1C), for ex-
ample CFTR mediated chloride transport in CF
mice, would obviously be precedent-setting. Final-
ly, generation of mice with enhanced or depleted
function of putative exogenously-derived lung
cells, and demonstration of an altered outcome af-
ter lung injury in either the native lung or in recip-
ients of bone marrow transplants from the mutant
mice, would provide functional evidence (figure
1D). It is important to note that, whether transdif-
ferentiation of exogenous cells to lung cell types is
ultimately deemed fact or fancy, circulating cells
are likely integral, if not vital, to healing and
strongly contribute to lung remodeling.
Embryonic stem cell (ES) generation of lung
cells. Pluripotent ES cells offer promise as a po-
tential source of lung endoderm, mesoderm, and
ectoderm cell types. Murine embryonic stem cells
grown as embryoid bodies, and then on collagen
coated surfaces with growth factors, followed by
replating at an air-liquid-interface developed into
an epithelium with Clara, ciliated, basal, and inter-
mediate cells [22]. Additional studies explored
conditions promoting mouse ES cell expression of
Type II cell genes [23-25]. Similar studies with hu-
man ES cells are likely imminent. Although an in-
tial report of somatic cell nuclear transfer (SCNT,
therapeutic cloning) to create human ES cells that
were pluripotent, chromosomally normal, and with
DNA and immunological haplotype identical to
the donor specimen has now been discredited [26],
it is likely that this technique will ultimately be ap-
plied to humans. Respiratory epithelium is com-
monly observed in teratomas derived from human
ES cells, and the ultimate success of SCNT with
human cells will enable study and potentially ther-
apeutic employment of a patient’s own cells. Re-
cent advances and setbacks highlight opportunities
for novel lung research using ES cells and the need
for more studies to determine the practical rele-
vance and safety of using ES cells for cell therapy.
In summary, many challenges remain to bet-
ter understand endogenous lung stem cells, to de-
termine the role of exogenous cells in lung injury,
repair and pathology, and to explore the potential
uses of ES cells. Developing rational strategies
for lung protective or regenerative cell therapy
will require an intensive and scientifically rigor-
ous effort.
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